

Agnes LABIGNE et al.
Serial No. 08/211,312

Attorney Docket No.: 2356.0074

IN THE CLAIMS:

Please cancel claims 18, 19, and 37-39 without prejudice or disclaimer and add the following new claims:

40. A purified polypeptide having the amino acid sequence of at least one of the polypeptides selected from the group consisting of UreE, UreF, UreG, UreH, and UreI, as shown in Figure 4 (SEQ. ID NOS: 4-7 and 3, respectively), or a fragment thereof.

41. The purified polypeptide of claim 40, wherein said polypeptide is UreE.

42. The purified polypeptide of claim 40, wherein said polypeptide is UreF.

43. The purified polypeptide of claim 40, wherein said polypeptide is UreG.

44. The purified polypeptide of claim 40, wherein said polypeptide is UreH.

45. The purified polypeptide of claim 40, wherein said polypeptide is UreI.

46. A purified polypeptide having an amino acid sequence expressed by a gene selected from the group consisting of ureE, ureF, ureG, ureH, and ureI (SEQ ID NO:1) of H. pylori, or a mutant thereof.

47. The purified polypeptide of claim 46, wherein said gene is ureE (SEQ ID NO:1) or a mutant thereof.

48. The purified polypeptide of claim 46, wherein said gene is ureF (SEQ ID NO:1) or a mutant thereof.

49. The purified polypeptide of claim 46, wherein said gene is ureG (SEQ ID NO:1) or a mutant thereof.

50. The purified polypeptide of claim 46, wherein said gene is ureH (SEQ ID NO:1) or a mutant thereof.

51. The purified polypeptide of claim 46, wherein said gene is ureI (SEQ ID NO:1) or a mutant thereof.

52. A purified polypeptide having the following amino acid sequence:

Ala Lys Ile Cys Tyr Glu Ile Gly Asn Arg His₁ (SEQ ID NO:9)

53. A purified antibody, which binds to the polypeptide according to any one of claims

54. A purified antibody, which binds to the polypeptide according to any one of claims

55. A purified antibody, which binds to the polypeptide according to claim 52.

56. A composition comprising the antibody of claim 53 and a pharmaceutically acceptable carrier.

57. A composition comprising the antibody of claim 54 and a pharmaceutically acceptable carrier.

58. A composition comprising the antibody of claim 55 and a pharmaceutically acceptable carrier.

59. A composition comprising the polypeptide of any one of claims 40-45 and a pharmaceutically acceptable carrier.

60. A composition comprising the polypeptide of any one of claims 46-51 and a pharmaceutically acceptable carrier.